EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated multi-omics analysis and functional experiments reveals PPAP2C as a potential prognostic biomarker and therapeutic target in breast cancer

Xiaoxi Lin, Lihang Cen, Sihui Yue, Liangsen Teng, Shuang Qin, Yipeng Cheng, Mingyue Qiu, Yonggang Lu, Jie Zhang, Shuguang Zuo

Frontiers in Pharmacology · 24.08.2026 · 17

DOI: 10.3389/fphar.2026.1884232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.08.2026. Verfasst von Xiaoxi Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chifeng Municipal Hospital, Chifeng Clinical Medical School, Inner Mongolia Medical University, Chifeng, Inner Mongolia, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to systematically elucidate the clinical significance and biological function of the phospholipid phosphatase (PLPP) family member (PPAP2C) phosphatidic acid phosphatase type 2C in breast cancer, and to evaluate its potential as a prognostic biomarker and therapeutic target.

Methods

Gene expression data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE) databases were integrated to characterize the expression profile of PLPP family members, focusing on PPAP2C in breast cancer. The prognostic value of PPAP2C, initially identified at the mRNA level (TCGA, (METABRIC) Molecular Taxonomy of Breast Cancer International Consortium, Gene Expression Omnibus (GEO)), was confirmed at the protein level by immunohistochemistry (IHC) on tissue microarrays (TMA). The oncogenic functions of PPAP2C were investigated in triple-negative breast cancer (TNBC) cells through CRISPR-Cas9-mediated knockout and ectopic overexpression, with assessment of key phenotypes including proliferation, colony formation, migration, and invasion. In vivo validation was subsequently performed using an MDA-MB-231 xenograft model.

Results

PPAP2C exhibits the most significant overexpression pattern across 33 cancer types (upregulated in 16 cancers, downregulated in only 3). Compared with normal tissues, PPAP2C showed specific overexpression in breast cancer tissues and was significantly associated with advanced clinical stages and aggressive subtypes (HER2 + and TNBC). Survival analysis demonstrated that high PPAP2C expression correlated with significantly shorter overall survival and disease-free survival, which was further validated in METABRIC and GEO cohorts. Tissue microarray analysis confirmed higher PPAP2C protein positivity in tumor tissues (94.7%) than in adjacent normal tissues (59.7%), with worse OS and RFS in high-expression groups. Multivariate analysis identified PPAP2C as an independent prognostic factor for OS. Functional experiments revealed that PPAP2C knockout (via 5-bp/1-bp frameshift mutations) suppressed TNBC cell proliferation, colony formation, migration, and invasion, while overexpression enhanced these phenotypes. In vivo studies further demonstrated complete tumor regression in MDA-MB-231 xenografts upon PPAP2C knockout.

Conclusion

This study identifies PPAP2C as a key oncogenic driver and a robust independent prognostic biomarker in breast cancer. The findings provide compelling evidence that PPAP2C represents a promising therapeutic target, offering a new strategic avenue for precision therapy, particularly for aggressive breast cancer subtypes.

Schlagwörter

Stichwörter der Autor:innen

PLPP2PPAP2Cbreast cancerprognostic biomarkertherapeutic target

Autor:innen und Institutionen

  • Chifeng Municipal Hospital, Chifeng Clinical Medical School, Inner Mongolia Medical University, Chifeng, Inner Mongolia, China.
  • Liuzhou Key Laboratory of Cancer Biotherapy, Liuzhou Municipal Liutie Central Hospital, Affiliated Liuzhou Hospital of Youjiang Medical University for Nationalities, Liuzhou, Guangxi, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lin, X., Cen, L., Yue, S., Teng, L., Qin, S., Cheng, Y., Qiu, M., Lu, Y., Zhang, J., & Zuo, S. (2026). Integrated multi-omics analysis and functional experiments reveals PPAP2C as a potential prognostic biomarker and therapeutic target in breast cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1884232

Vancouver

Lin X, Cen L, Yue S, Teng L, Qin S, Cheng Y, et al. Integrated multi-omics analysis and functional experiments reveals PPAP2C as a potential prognostic biomarker and therapeutic target in breast cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1884232

BibTeX
@article{Lin2026,
  author = {Lin, Xiaoxi and Cen, Lihang and Yue, Sihui and Teng, Liangsen and Qin, Shuang and Cheng, Yipeng and Qiu, Mingyue and Lu, Yonggang and Zhang, Jie and Zuo, Shuguang},
  title = {Integrated multi-omics analysis and functional experiments reveals PPAP2C as a potential prognostic biomarker and therapeutic target in breast cancer},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1884232}
}
Kostenlos starten →